No profile data available.
Entera Bio Ltd. (ENTX) is a healthcare company in the bone and joint treatment drugs industry, based in Jerusalem, Israel, with about 20 full-time employees.
It reported revenue of $42,000 for fiscal year 2025, down 76.8% from fiscal year 2024, and net income of -$11.44 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $462.40 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Entera Bio reported $42,000 in revenue for fiscal year 2025, down 76.8% from $181,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$462.40 million as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment drugs) include Eupraxia Pharmaceuticals Inc. (EPRX), Mereo BioPharma Group plc (MREO), Dogwood Therapeutics, Inc. (DWTX), Enlivex Therapeutics Ltd. (ENLV).